ATE489622T1 - Verfahren zur beurteilung der malignität einer säuger-krebszelle - Google Patents

Verfahren zur beurteilung der malignität einer säuger-krebszelle

Info

Publication number
ATE489622T1
ATE489622T1 AT05743830T AT05743830T ATE489622T1 AT E489622 T1 ATE489622 T1 AT E489622T1 AT 05743830 T AT05743830 T AT 05743830T AT 05743830 T AT05743830 T AT 05743830T AT E489622 T1 ATE489622 T1 AT E489622T1
Authority
AT
Austria
Prior art keywords
sensitivity
ratio
assessing
anticancer agent
irritant
Prior art date
Application number
AT05743830T
Other languages
English (en)
Inventor
Hideki Ishihara
Tomoko Matsushima
Yuko Kawasaki
Original Assignee
Sysmex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sysmex Corp filed Critical Sysmex Corp
Application granted granted Critical
Publication of ATE489622T1 publication Critical patent/ATE489622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
AT05743830T 2004-05-31 2005-05-30 Verfahren zur beurteilung der malignität einer säuger-krebszelle ATE489622T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004160389 2004-05-31
JP2004375639 2004-12-27
PCT/JP2005/009847 WO2005116241A1 (ja) 2004-05-31 2005-05-30 哺乳動物細胞の性質判定方法及びこれを用いた癌の診断方法

Publications (1)

Publication Number Publication Date
ATE489622T1 true ATE489622T1 (de) 2010-12-15

Family

ID=35450902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05743830T ATE489622T1 (de) 2004-05-31 2005-05-30 Verfahren zur beurteilung der malignität einer säuger-krebszelle

Country Status (6)

Country Link
US (1) US8921057B2 (de)
EP (1) EP1767647B1 (de)
JP (1) JP4787153B2 (de)
AT (1) ATE489622T1 (de)
DE (1) DE602005024964D1 (de)
WO (1) WO2005116241A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840221A1 (de) * 2006-03-31 2007-10-03 Sysmex Corporation Verfahren zum Messen der Kinaseaktivität
JP4989127B2 (ja) * 2006-06-30 2012-08-01 シスメックス株式会社 チロシンキナーゼの活性測定方法及びチロシンキナーゼの基質
JP5283872B2 (ja) * 2006-09-27 2013-09-04 シスメックス株式会社 腫瘍細胞に対する阻害剤の増殖抑制効果を評価する方法、及び腫瘍細胞の増殖を阻害する化合物をスクリーニングする方法
JP5111902B2 (ja) * 2007-03-14 2013-01-09 シスメックス株式会社 癌の診断支援装置
US8921114B2 (en) 2007-08-24 2014-12-30 Sysmex Corporation Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product
JP5405059B2 (ja) * 2007-08-24 2014-02-05 シスメックス株式会社 がんの診断支援システム、がんの診断支援情報提供装置及びがんの診断支援情報提供方法
JP5274808B2 (ja) * 2007-10-02 2013-08-28 シスメックス株式会社 がんの診断支援システム
JP2009089672A (ja) * 2007-10-10 2009-04-30 Sysmex Corp がんの再発リスクの判定方法
JP5351427B2 (ja) 2008-03-28 2013-11-27 シスメックス株式会社 癌の再発リスクを判定する方法及び癌の再発リスク診断の支援方法
JP5340621B2 (ja) * 2008-03-28 2013-11-13 シスメックス株式会社 アンスラサイクリン系抗がん剤治療の有効性を判定する方法、及びアンスラサイクリン系抗がん剤治療の有効性の診断支援方法
JP2009240238A (ja) * 2008-03-31 2009-10-22 Sysmex Corp アンスラサイクリン系抗がん剤に対するがん細胞の感受性の判定方法及び判定装置
JP2010057486A (ja) * 2008-09-02 2010-03-18 Sysmex Corp 化学療法に対するがん患者の応答の予測方法
AT508680B1 (de) * 2009-05-19 2011-03-15 Onkotec Gmbh Verfahren zur qualitativen und/oder quantitativen bestimmung von tumorzellen
JP5758690B2 (ja) * 2011-04-27 2015-08-05 シスメックス株式会社 併用化学療法の奏効性判定方法、奏効性判定プログラム及び奏効性判定装置
JP6002379B2 (ja) 2011-11-29 2016-10-05 シスメックス株式会社 癌の再発リスクの判定方法及びその利用
JP2020162420A (ja) * 2019-03-28 2020-10-08 シスメックス株式会社 サイクリン依存性キナーゼ４／６阻害剤の感受性を判定するための方法、試薬キット、装置及びコンピュータプログラム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705865B2 (en) * 1996-02-08 1999-06-03 Darwin Discovery Limited Resolution of 4-cyano-4-(3,4-dimethoxyphenyl) -5-methylhexanoic acid
DE19734893A1 (de) 1997-08-12 1999-02-18 Emtec Magnetics Gmbh Lösungsmittelfrei herstellbare Polyurethane und ihre Verwendung als Bindemittel für magnetische Aufzeichnungsträger
JPH11166931A (ja) * 1997-12-05 1999-06-22 Sysmex Corp 生体成分の量的あるいは質的異常を検出する方法
AU741712B2 (en) 1998-02-18 2001-12-06 Theryte Limited Treating cancer
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
ATE393821T1 (de) * 2001-02-14 2008-05-15 Sysmex Corp Verfahren zur bestimmung der aktivität des zellzyklus-regulationsfaktors und verfahren zur diagnose von krebs unter verwendung desselben
JP4036655B2 (ja) 2001-02-14 2008-01-23 シスメックス株式会社 細胞周期調節因子の活性の測定法と該測定法に使用される試薬
DK1388734T3 (da) * 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
WO2004076686A1 (ja) 2003-02-26 2004-09-10 Sysmex Corporation 細胞の検査方法
US7957910B2 (en) * 2005-01-31 2011-06-07 Sysmex Corporation Method for predicting effectiveness of chemotherapy

Also Published As

Publication number Publication date
US8921057B2 (en) 2014-12-30
JPWO2005116241A1 (ja) 2008-04-03
EP1767647B1 (de) 2010-11-24
EP1767647A1 (de) 2007-03-28
DE602005024964D1 (de) 2011-01-05
WO2005116241A1 (ja) 2005-12-08
EP1767647A4 (de) 2007-08-29
JP4787153B2 (ja) 2011-10-05
US20070231837A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
ATE489622T1 (de) Verfahren zur beurteilung der malignität einer säuger-krebszelle
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
NZ588638A (en) Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
BR112014018192A8 (pt) método e kit para detecção de células tumorais circulantes 5t4-positivas, bem como métodos de diagnóstico de câncer 5t4-positivo e de seleção para atividade e eficácia de conjugado fármaco-anticorpo para tratamento de câncer
BRPI0519570A2 (pt) mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
ATE426806T1 (de) Verfahren zur prognose der wirksamkeit von chemotherapie
BRPI0608043A2 (pt) composição, método que promove a regressão do tumor, linhagem celular, método de identificação de um agente quimioterapêutico, método que promove a apoptose em células do tumor de mama, método de identificação de um agente que aumenta a apoptose em uma célula, uso de um agente e uso do ácido d-ala-l-glu-diaminopimélico
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
BR112013004278A2 (pt) tintas de reagente enzimático para uso em tiras de teste tendo um código de calibração predeterminado
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2007090125A3 (en) Prognostic factors for anti-hyperproliferative disease gene therapy
GB0900151D0 (en) rapid bioluminescence detection system
Spina et al. Liquid biopsy in tissue-born lymphomas
ATE459002T1 (de) Verfahren zur einschätzung des risikos maligner tumorrezidive
WO2020123880A3 (en) Genomic rearrangements associated with prostate cancer and methods of using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties